Literature DB >> 16168711

Scleroderma: from cell and molecular mechanisms to disease models.

David J Abraham1, John Varga.   

Abstract

Scleroderma [also known as systemic sclerosis (SSc)] is a complex autoimmune disease characterised by pathological remodelling of connective tissues. Although the earliest and most frequent manifestations include blood vessel and immunological abnormalities, the systemic and progressive pathology suggests that fundamental interactions between microvascular damage and inflammation are mechanistically linked to obliterative tissue fibrosis. This review will focus on how model systems have provided clues to these relationships and will discuss new data from the study of novel animal disease models. These reveal how vascular damage and leukocyte accumulation generate the molecular cues that control the profiles of soluble mediators, which regulate the aberrant behaviour of mesenchymal cells within connective tissues, and how the dysregulated expression of these components and their differentiation contribute to the persistent fibrogenic response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168711     DOI: 10.1016/j.it.2005.09.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  91 in total

1.  The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Authors:  Feng Fang; Kohtaro Ooka; Swati Bhattacharyya; Swati Bhattachyya; Jun Wei; Minghua Wu; Pan Du; Simon Lin; Francesco Del Galdo; Carol A Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors:  Iman H Bassyouni; Roba M Talaat; Tarek A Salem
Journal:  J Clin Immunol       Date:  2011-10-07       Impact factor: 8.317

3.  Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.

Authors:  Christina D Keller; Pilar Rivera Gil; Markus Tölle; Markus van der Giet; Jerold Chun; Heinfried H Radeke; Monika Schäfer-Korting; Burkhard Kleuser
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

Authors:  Thomas A Wynn
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 5.  Novel paradigm for treating vasculopathy in systemic sclerosis: vascular progenitor cells and statins.

Authors:  Monique Hinchcliff; John Varga
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

6.  Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies.

Authors:  Nezam Altorok; Pei-Suen Tsou; Patrick Coit; Dinesh Khanna; Amr H Sawalha
Journal:  Ann Rheum Dis       Date:  2014-05-08       Impact factor: 19.103

Review 7.  Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.

Authors:  Michael Zeisberg; Raghu Kalluri
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-19       Impact factor: 4.249

8.  Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension.

Authors:  Melahat Melek Oguz; Ayse Deniz Oguz; Cihat Sanli; Ayhan Cevik
Journal:  Tex Heart Inst J       Date:  2014-04-01

Review 9.  Oxidative and nitrosative stress and fibrogenic response.

Authors:  R Urtasun; L Conde de la Rosa; N Nieto
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 10.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.